ArticleChest2025
Characterizing Patients With Sarcoidosis With Obstructive Respiratory Physiology.
Article in Chest, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLung involvement occurs in > 95% of sarcoidosis cases. The World Association of Sarcoidosis and Other Granulomatous Disorders Organ Assessment Instrument does not assign the likelihood of lung involvement based on pulmonary function test (PFT) results. Clinical characteristics linked to normal and abnormal physiologic pattern on PFTs in sarcoidosis are incompletely understood. RESEARCH QUESTION: What is the frequency of obstructive physiology (OP), restrictive physiology (RP), or normal physiology in patients with sarcoidosis, and are there laboratory parameters linked to these different patterns? STUDY DESIGN AND
methodsWe evaluated 253 patients with sarcoidosis according to their PFT findings and grouped them into OP, RP, and normal spirometry. These PFTs were correlated to demographic, clinical, and laboratory parameters. In some cases, the PFT abnormalities were correlated with proteins in the Olink metabolic and immune response protein panels.
resultsOf the 253 cases studied, 64% had normal spirometry, 20% had OP, and 15% had RP. Abnormal PFT findings were more frequent in male individuals, with 61.2% of the OP group and 82.1% of the RP group (P = .002). The average lymphocyte percentage was lower in OP vs RP (normal, 21.5%; OP, 17.3%; RP, 23.7%; P = .04), soluble IL-2 receptor was lower in OP vs normal (normal, 632.1 U/mL; OP, 335.5 U/mL; RP, 563.4 U/mL; P = .026), and C-reactive protein was lower in OP vs RP and in normal vs RP (normal, 11.7 mg/L; OP, 8.2 mg/L; RP, 35.6 mg/L; P = .018). Those with RP had less splenic involvement (normal, 21.5%; OP, 21.6%; RP, 2.6%; P = .008). Five immune response proteins had differential abundance in the three comparison groups.
interpretationMost of the sarcoidosis study cohort had normal spirometry findings. When abnormal, OP was more common than RP. There may be a difference in immune mechanisms in those with OP compared with those with RP or normal spirometry values. Continued comprehensive assessments of serum proteins may identify biomarkers to identify physiologic abnormalities and guide management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.